Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer’s Disease
TOKYO, Jan 7, 2025 – (JCN Newswire) – A collaborative research group led by Professor Kenjiro Ono of the Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, and Eisai Co., Ltd., used a newly developed measurement system for lecanemab-associated amyloid-β protofibrils (Lec-PF) to demonstrate that the concentration of Lec-PF in human cerebrospinal fluid is
TOKYO, Jan 7, 2025 – (JCN Newswire) – A collaborative research group led by Professor Kenjiro Ono of the Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, and Eisai Co., Ltd., used a newly developed measurement system for lecanemab-associated amyloid-β protofibrils (Lec-PF) to demonstrate that the concentration of Lec-PF in human cerebrospinal fluid is elevated in patients withAlzheimer’s disease at all stages…
Read More
About Author
